Metastatic breast cancer: why are we here and where are we going?

European Journal of Cancer, Supplement

Volumn 4, Issue 13, 2006, Pages 2-5

  Crown, John ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Chemotherapy; Metastatic breast cancer; Molecularly targeted therapy; Survival; Trastuzumab

Indexed keywords

ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; LETROZOLE; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PREDNISOLONE; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; MEDICAL RESEARCH; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 33847060356     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(07)70002-2     Document Type: Article

References (22)

1. Jemal A., Siegal R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2002) 106-130
2. Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol 33 1 Suppl 2 (2006) S2-S5
3. Greenspan E., Fieber M., Lesnick G., and Edelman S. Response of advanced breast carcinoma to the combination of the antimetabolite, methotrexate, and the alkylating agent thio-TEPA. J Mt Sinai Hosp NY 30 (1963) 246-267
4. Chia S., Speers C., Kang A., et al. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. Proc Am Soc Clin Oncol 22 (2003) Abstract 22.
5. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2205, 10 (Suppl 3), 20-9.
6. Coates A., Gebski V., Bishop J., et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317 24 (1987) 1490-1495
7. Muss H., Case L., Richards F., et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 325 (1991) 1342-1348
8. French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 18 (2000) 3115-3124
9. Gennari A., Amadori D., De Lena M., et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24 (2006) 3912-3918
10. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17 8 (1999) 2341-2354
11. Nabholtz J., Falkson C., Campos D., et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21 6 (2003) 968-975
12. Tubiana-Hulin M., Bonneterre J., Bougnoux P., et al. Better survival with epirubicin-docetaxel (ET) combination as first-line chemotherapy in patients with metastatic breast cancer (MBC): final results of a phase II randomized study. Proc Am Soc Clin Oncol 22 (2003) Abstract 182.
13. Bontenbal M., Creemers G.-J., Braun H., et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 23 28 (2005) 7081-7088
14. Mackey J., Paterson A., Dirix L., et al. Final results of the phase III randomised trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21 (2002) Abstract 137.
15. Seidman A., Berry D., Cirrincione C., et al. CALGB 9840: Phase III of weekly (W) paclitaxel (P) via 1 -hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 22 14S (2004) Abstract 512.
16. Albain K., Nag S., Calderillo-Ruiz G., et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 22 14 Suppl (2004) Abstract 510.
17. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 (2002) 2812-2823
18. Slamon D., Clark G., Wong S., Levin W., Ullrich A., and McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 4785 (1987) 177-182
19. Slamon D., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
20. Piccart-Gebhart M. First results of the HERA trial. In: Advances in monoclonal antibody therapy for breast cancer. Annu Meet Am Soc Clin Oncol (2005)
21. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC -> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC -> TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Proc San Antonio Breast Cancer Symposium 2005, Abstract 1.
22. Miller K, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Proc San Antonio Breast Cancer Symposium, 2005, Abstract 3.